Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Jefferies resumes coverage of Drax at 'buy'

(Sharecast News) - Jefferies resumed coverage of Drax on Monday with a 'buy' rating and 750p price target, saying it was "resilient" amid uncertainty. Following the FY24 results and the agreement of heads of terms with the UK government on a biomass bridging mechanism, Jefferies updated its model and said it sees increased post-2027 earnings visibility, which is helpful.

The bank estimated more than £600m of EBITDA for 2027 and beyond, where the new datapoint since its last update in December 2024 is the established contribution from biomass generation where Drax expects around £100-200m of EBITDA over the period of the bridging mechanism.

"Following our refresh, our FY25-27 EBITDA/EPS estimates are 2%/5% above Visible Alpha consensus," it said.

Jefferies also said it sees a limited impact on Drax in the case of zonal pricing being introduced.

"Our understanding is that the potential introduction of zonal pricing to the UK will have little material impact on Drax's revenue streams," it said. "Where there may be some positive exposure is on Drax's OCGT plants, which are due to be commissioned in 2025.

"These assets are located in the south of the UK, where prices/margins might increase under zonal pricing."

Conversely, Jefferies said, zonal pricing may have a negative read-across for hydro assets.

The bank also said in the note that it sees upside on Drax from the potential increase in the buyback programme, on top of the current £300m programme.

"This comes against the backdrop of investment uncertainty, as well as due to them being recently outbid for battery storage in the UK."

It noted that Drax secured permission at the May annual general meeting to go ahead with additional buybacks, equivalent to around 10% of shares outstanding as of March 2025.

This is underpinned by a robust balance sheet, it added.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.